India’s Clopidogrel prices moved sharply upward during May 2026, supported by strong institutional procurement and tightening domestic availability. Early-month Jan Aushadhi tenders accelerated bulk purchases of Clopidogrel ahead of the monsoon quarter, while hospital procurement and precautionary stocking by large healthcare chains absorbed a significant portion of available supply. Domestic Clopidogrel producers operated cautiously following recent US FDA re-inspections, prioritizing compliant batch production and limiting immediate supply growth. Meanwhile, exports of Clopidogrel weakened as buyers in Russia and Brazil shifted toward lower-priced Chinese alternatives, reducing overseas demand pressure. Rising feedstock costs for intermediates such as methyl lactate and pyridine derivatives, combined with higher coal-based electricity tariffs, further strengthened Clopidogrel production costs. Looking forward, the Clopidogrel market is expected to remain firm amid sustained domestic procurement activity and elevated manufacturing costs.
